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Abstract
 Abdominal aortic aneurysm (AAA) is a disease affecting the main artery transporting oxidized blood to the 
abdominal and pelvic organs. Abdominal aortic aneurysms occur 4-8 times more often in men than in women, 
usually develop after the age of 55. Among men over 65, 4–7.6%, this diagnosis can be expected. More aneu-
rysms occur in Caucasian people. Among the most frequently mentioned in the literature, AAA risk factors are 
older age, male gender, positive family history, smoking, chronic obstructive pulmonary disease, hypertension, 
hypercholesterolemia, peripheral arterial occlusive disease, ischemic heart disease. Biochemical tests to deter-
mine the level of AAA-specific markers appear with potential. There are reports in the literature on the possible 
use of concentrations of selected molecules in the diagnosis of AAA. According to cadaveric research, there are 
noticed dimensions of the abdominal aorta at its different levels. The relation between aortic size and shape 
can be the factor contributing to the development of AAA. Previous studies have shown that the development 
of AAA is a crucial fundamental inflammatory response in conjunction with proteolysis tissue, which causes the 
destruction and reconstruction of the blood vessel wall. Numerous factors contribute to the pathogenesis of 
AAA: proteins, transcription factors, enzymes and microRNAs. The increase in the concentration of most factors 
is associated with inflammation. The biomarkers presented in the paper are not limited to AAA, and thus can 
be used only for visual assessment of the degree of abdominal aortic aneurysm development.
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Introduction
An abdominal aortic aneurysm (AAA) is a local 
dilatation above 30 mm of the vessel diameter located 
below the renal arteries [1–3]. Widening of the aorta is 
usually bag-shaped, less sparse fusiform [4]. Widening 
of the abdominal aorta above 50 mm is a significant 
clinical problem because there is a high risk of its 
rupture, which is a direct threat to a patient’s life [5]. 
The indication for AAA surgery is the vessel diameter 
exceeding 55 mm, symptomatic or ruptured. 
Epidemiological data indicate that AAA occurs in 
4.4% of the population age of 40 years and older. 
This disease mainly affects men, in whom it is 3 to 
8 times more frequent than in women. Among the 
population aged 60–65, AAA suffers from 3% of men. 
AAA occurs in 9% of men over 75 years of age. [6]. 
In the recent 20 years, the number of AAAs cases in-
creased due to the ageing of the population and to the 
increase in the early detection of this condition. Very 
often, the first symptom of AAA is its rupture. Some 
40% of patients die from unrecognized AAA [7]. 
AAA is the cause of 1-3% of deaths in the popula-
tion aged between 65 and 85 years in economically 
developed countries. Very rarely, aneurysms are 
diagnosed in children [8]. 
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There are three main types of AAA: (I) asympto-
matic, (II) symptomatic and (III) cracked. An additional 
type of AAA is an inflammatory aneurysm representing 
about 10% of the cases. Another AAA classification 
constitutes such categories as: (1) due to the etiology 
— atherosclerotic, degenerative syndrome (Marfan 
syndrome, Ehlers and Danlos syndrome type IV, aortic 
cyst degeneration), post-inflammatory (Takayasu dis-
ease, giant cell arteritis, systemic inflammation, syphilis, 
endocarditis, sepsis) and post-traumatic; (2) due to the 
shape of AAA — a baggy (usually in the subclavian artery 
of the left or the lower wall of the aortic arch), fusiform 
(much more frequent); (3) due to the construction of 
the wall — true, alleged (the wall creates adventitia 
with surrounding tissues after the internal and middle 
membrane is disrupted, most often post-traumatic); 
(4) due to the clinical pattern - asymptomatic, sympto-
matic, and broken and (5) due to the location — tho-
racic (usually ascending aorta), abdominal (below the 
diaphragm, aneurysm in the subrenal section constitute 
~ 90% of aortic aneurysms), thoraco-abdominal [9]. 
At the symptomatic stage, the risk of rupture of the 
abdominal aortic aneurysm within 5 years is 2% with 
a diameter of < 40 mm, 3 to 12% with a diameter of 
40 to 50 mm, 25 to 40% with a diameter of > 50 mm [9]. 
Mortality due to AAA rupture is estimated at about 
40 to 60%. Usually, AAA is detected accidentally, for 
example during an ultrasound examination. Biochemical 
tests to determine the level of AAA-specific biomarkers 
seem to be very promising [10]. There are reports in the 
literature about the possibility of using the concentra-
tion assessment of selected molecules in the diagnosis 
of AAA (Table 1). 
Risk factors for AAA
Numerous risk factors might contribute to AAA devel-
opment (Fig. 1). The most prominent are hypertension, 
smoking, male sex age > 75 years, atherosclerosis, 
chronic obstructive pulmonary disease and positive family 
history for AAA including genetic background with gene 
mutations. Genetic predisposition is very important in 
assessing the risk of AAA. Results of studies revealed 
that AAA occurs in 25% of people who are relatives 
of the first degree to people with this disease. About 
20% of people with AAA have genetic-based diseases, 
such as Marfan’s or Ehlers-Danlos syndromes [19–23]. 
It is also worth to mention that smoking is a risk factor 
in developing this disease and every additional year of 
smoking increases the AAA risk by 4% [24].
Anatomical and histological aspects  
of the abdominal aorta 
The abdominal aorta is formed due to the fusion of the 
two dorsal aortae in a caudo-cranial fashion. Congen-
Table 1. Selected AAA biomarkers
Biomarker Structure Reference
Homocysteine Amino acid [11]
Osteoprotegerin Protein [12]
Osteopontin Protein [12]
miRNA712/205
miRNA 29c-3p Micro RNA [13, 14]
Interleukins: 2, 6, 10 Proteins [15]
C-reactive proteins (CRP) Protein [15]
a1-antiproteinase Protein [16]
antithrombin III (AT-III) Protein [16]
Cystatin C Protein [16
ELF1, ETS2, RUNX1, STAT5 Transcription factors, proteins [17]
Metalloproteinases: MMP-2, MMP-3, MMP-9, MMP-14 Proteins [18]
Figure 1. Identified and putative risk factors of AAA
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ital narrowing or coarctation of the aorta is primarily 
a defect of the tunica media, followed by proliferation 
of the tunica intima. Most of the changes in the caliber 
of abdominal aorta occur in later ages and are acquired. 
Tortuosity of abdominal aorta may be considered as 
a geometrical risk factor in the development of the 
abdominal aortic aneurysm. Abdominal aorta has 
a tendency to develop tortuosity with age due to loss 
of longitudinal stiffness [25].
The caliber of the abdominal aorta decreases 
downwards. According to cadaveric research (Fig. 2) 
by Mandal et al. [25], there were noticed dimensions 
of the abdominal aorta at its different levels (Table 2). 
The relation between aortic size and shape can prob-
ably be a factor contributing to the development of 
AAA [25–27]. Knowing the diameters, thickness and 
tortuosity of the abdominal aorta and their linkage to 
the danger of aneurysm and rupture are very important 
for clinicians and vascular surgeons [25]. According to 
Liu et al. [28], the arterial buckling could be a possible 
mechanism for the initiation of tortuous shape. The 
experimental studies revealed that under pulsatile 
pressure, the arteries buckled when the peak pressures 
were roughly equal to the critical buckling pressures 
under static pressure [27]. The stability of blood vessels 
under the lumen blood pressure is essential to the main-
tenance of normal arterial functioning [23]. Han [28] 
reported that arteries could buckle due to high blood 
pressure or low axial tension. Therefore, the residual 
stress in the arteries increases the buckling pressure. 
At junctions, such as the aortic bifurcation, transferred 
pressure waves may weaken the inner layer. The differ-
ence in luminal diameters of common iliac arteries may 
initiate turbulence in blood flow, damaging the intimal 
lining of the distal abdominal aorta [24, 25, 28]. The 
rupture of abdominal aortic aneurysm occurs when 
the mechanical stress acting on the inner wall, due to 
intraluminal pressure, exceeds the failure strength of 
the degenerated aortic tissue [29, 30].
Pathophysiological mechanisms  
of abdominal aorta development
The reason for the initiation of degradation changes in 
the blood vessel wall is poorly understood. Numerous 
factors are proposed to be involved at different stages 
of aneurysm development (Fig. 3). An abdominal aortic 
aneurysm is the final result of irreversible pathological 
remodelling of the extracellular matrix (ECM) [31, 32]. 
ECMs ensure a relevant mechanical environment to 
which vascular tissue is continuously exposed. The 
main building blocks of the aortic wall are elastin and 
collagens [31]. On the contrary to elastin, which is a 
stable protein having half-life time measured in tens of 
years, collagens are normally remodelled by means of 
their continues deposition and degradation [32, 33]. 
Table 2. Dimensions of abdominal aorta at different levels [25]
Site Diameter (cm)
Upper pole of left kidney 7
2 cm below origin of SMA 7.2*
The lower pole of left kidney 5.8
At the origin of IMA 5.5
Just before bifurcation 5.3**
*Thickest; **Thinnest; SMA: superior mesenteric artery; IMA: inferior mesen-
teric artery
Figure 3. A — schematic construction of the aortic wall; B — pathological pathways of AAA development [32–38]
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Vascular collagens have a half-life time of 60–70 days 
under physiological conditions, which decreases by up 
to 10-fold in case of disease and injury [34, 35]. The 
rupture of AAA occurs when the mechanical stress 
acting on the inner wall, due to intraluminal pressure, 
exceeds the failure strength of the degenerated aortic 
tissue [36].
Changes leading to the damage to the vessel wall 
relate to degradation of wall building components and 
the presence of inflammation within its walls. Under the 
influence of a damaging factor or as a result of induc-
tion with substances coming from disintegrating cells, 
cells present in the vascular wall such as macrophages, 
lymphocytes or smooth muscle cells produce cytokines 
and inflammatory mediators that are involved in the 
formation, as well as regulation of proteolytic enzymes 
responsible for the destruction of the abdominal aorta’s 
wall. Activated lymphocytes producing interleukin-2 
(IL-2), tumour necrosis factor alpha (TNF-a) and 
interferon gamma (INF-g) increase the proteolytic 
activity of macrophages. These macrophages are in 
turn a source of metalloproteases, responsible for the 
digestion of elastin, collagens, fibronectin, lamina and 
proteoglycans [15, 37–40]. The reduced content of 
elastin, as well as collagens and fibronectin, is a potential 
source of loss of elastic as well as mechanical proper-
ties of the aorta, thus, increasing the vessel diameter 
and creating a baggy dilation, called aneurysm [15]. 
Maintaining the proteolytic homeostasis protects the 
structural proteins of the aortic wall from degradation. 
Shifting this balance in the favour of proteinases causes 
uncontrolled degradation of these proteins and leads 
to the formation, the enlargement and the aneurysm 
rupture [41, 42]. Frequent coexistence in patients with 
atherosclerotic TAB the coronary artery disease (CAD) 
and/or peripheral vascular disease (PAD) suggests the 
involvement of atherosclerotic lesions in increasing 
the risk of developing this disease. Some authors 
proposed that the abdominal aortic aneurysm is some 
kind of atherosclerosis [43]. Previous research results 
indicate that in the development of an abdominal aortic 
aneurysm, a major inflammatory reaction combined 
with tissue proteolysis, which results in the destruction 
and reconstruction of the blood vessel wall, is of key 
importance. However, much of the controversy results 
from the nature of the cellular response and the type of 
factors modulating the inflammatory response [44, 45]. 
A role of homocysteine in the creation  
of abdominal aorta aneurysm
Homocysteine is a thiol amino acid formed in all cells 
in the methionine - cysteine pathway. Its normal con-
centration in blood should not exceed 14 mol/l on an 
empty stomach and 30 to 38 mol/l after 6 hours from 
methionine loading [11]. Mild hyperhomocysteinemia 
occurs in approximately 5 to 7% of the population, 
whereas a significantly elevated level of this amino acid 
in the blood is observed in 20–40% of people suffering 
from cardiovascular disease [46]. Studies revealed that 
elevated levels of homocysteine occur in about 50% of 
people with AAA [47]. The main mechanisms leading to 
the development of AAA are inflammation within the 
vessel wall, degradation of connective tissue elements 
(elastin, collagens), mechanical injuries and genetic 
predisposition. Thus, the homocysteine presence at 
abnormal concentrations might affect any of the listed 
pathogenic mechanisms of AAA [48].
Elevated levels of homocysteine in the blood have 
toxic effects on the endothelium of blood vessels. Hy-
perhomocysteinemia activates the enzyme called asym-
metric dimethylarginine (ADMA), which is an inhibi-
tor of the endothelial isoform of nitric oxide synthase 
(eNOS) (Fig. 4). The reduction in eNOS activity results 
in a decrease in NO concentration, which impairs the 
vasodilating capacity of vascular endothelial cells [49]. 
Decreasing NO concentration leads to disturbance 
of a balance between vasodilating abilities in favour of 
vasoconstriction capacity. Proteolytic capacity increases 
and the concentrations of prostaglandin G2 (PGI2) are 
reduced, while the production of endothelin 1 (ET-1), 
angiotensin II, thromboxane A2 (TXA2) increases (Fig. 4). 
Hyperhomocysteinemia leads to impaired hemostasis 
(Fig. 4) resulting in the formation of a blood clot in the 
walls of the blood vessels. The impairment of vascular 
endothelial anticoagulant function is the basic pathogenic 
mechanism of AAA development [50]. Methyltetrahy-
drofolate reductase (MTHFR) is an enzyme responsible 
Figure 4. Pathophysiological consequences of hyperhomocysteinemia [49–51]
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for the re-methylation of homocysteine to methionine, 
thereby lowering the homocysteine concentration. Results 
of studies have revealed that polymorphisms affecting 
the activity of this enzyme may occur within the MTHFR 
gene [51–53]. The most frequent mutation in the MTHFR 
gene is the point mutation of the substitution of cytosine 
(c) for thymine (t) at position 677: C677 Æ T, resulting 
in the change Ala222Val. As a result of this mutation, the 
enzyme N5-N10-methyltetrahydrofolate is formed, which 
is characterized by reduced activity, which promotes the 
development of hyperhomocysteinemia [53].
There is no doubt that hyperhomocysteinemia is the 
result of just having an effect on AAA [54]. Spark et al. [55] 
reported that the elevated concentration of this ami-
no acid occurred in 53% of AAA subjects. However, 
these researchers did not show a relationship between 
the level of homocysteine concentration and the size 
of the abdominal aortic aneurysm. Brunelli et al. [56] 
proposed that in people with higher concentrations of 
homocysteine, the size of aneurysms was larger when 
compared to patients with a lower concentration of this 
amino acid. This is most likely related to the fact that 
an increased level of homocysteine leads to a throm-
botic aortic clot, which makes access to extracellular 
matrix components difficult for enzymes degrading its 
components, such as elastin [56, 57].
Roles of osteoprotegerin and osteopontin 
in the abdominal aorta aneurysm
Osteoprotegerin is an osteoneogenesis-inhibiting fac-
tor, probably a calcification inhibitor, which prevents 
the formation of calcium deposits. Osteoprotegerin 
in combination with RANKL prevents the formation 
of the RANKL-RANK complex and thus blocks the 
activation of osteoclasts [58]. Osteopontin binds Ca2+ 
with high affinity and enhances bone resorption by 
coating hydroxyapatites by osteoclasts. It is an inhibitor 
of hydroxyapatite crystallization in vitro and inhibits the 
binding of the cell adhesion molecule with apatite (crys-
tal growth). Osteopontin is produced by osteoclasts and 
is responsible for the adhesion of macrophages [59]. 
Numerous study reports have shown that both, 
osteopontin and osteoprotegerin are involved in the 
activation of immune system cells and exacerbate 
atherosclerotic lesions resulting from an increase in 
calcification of the walls of blood vessels [58–60]. In 
the study of patients with AAA and Leriche’s syndrome, 
manifested by a set of symptoms caused by stenosis or 
obstruction of the final segment of the abdominal aorta 
and/or iliac arteries, higher concentrations of osteopro-
tegerin and osteopontin in the group with AAA were 
detected. The study also revealed that higher concen-
trations of osteopontin are characteristic in patients 
with AAA with concomitant coronary artery disease, 
while higher concentrations of osteoprotegerin are 
characteristic in patients with AAA after a stroke. There 
was no correlation between the level of osteoprote-
gerin and osteopontin concentration and the diameter 
of the abdominal aortic aneurysm. Moreover, a positive 
correlation between the concentration of osteopontin 
and C-reactive protein (CRP) has been detected, which 
confirms its pro-inflammatory nature [61, 62].
MicroRNAs in the abdominal  
aorta aneurysm
 MicroRNA 712/205 (miR-712/205) is a tissue inhibitor 
of metalloproteinase-3 inhibitor (TIMP3). In the AAA 
mouse model, the concentration of the miR-712/205 
was higher [63]. miR-712/205 also has an inhibitory 
effect on a2-macroglobulin, which is a membrane-an-
chored reversion-inducing-cysteine-rich glycoprotein 
(RECK), inhibiting the activity of MMP-9, MMP-2 and 
MMP-14 [64]. The increased concentration of miR-
712/205 leads through the inhibition of TIMP3 and 
RECK to the increased activity of MMPs, especially 
MMP3. The increased activity of MMPs leads to the 
development of inflammation and degradation of the 
connective tissue components within the aortic wall, 
which increases the risk of AAA development [65]. 
Elevated levels of miRNA 29c-3p in patients with AAA 
were reported by Lichołai et al. [13]. These research-
ers compared the serum composition of patients with 
AAA with the serum composition of patients without 
AAA found an increased concentration of mi-29c-3p, 
which correlated with the diameter of the aneurysm. 
Elevated concentration of miR-29c-3p in vitro led to the 
lower expression of genes such as elastin encoding gene 
(ELN), the gene coding for collagen type IV alpha-1 chain 
(COL4A1), the gene for phosphatase and tensin homolog 
(PTEN), a gene coding for vascular endothelial growth 
factors isoform A (VEGFA). The results suggest that 
elevated miR-29c-3p is a potential serum biomarker for 
AAA because inhibition of genes encoding proteins of 
the vascular wall matrix components (aortas) leads to 
greater susceptibility to aneurysm development [13]. 
Roles of interleukins 2, 6, 10  
and c-reactive protein in the  
abdominal aorta aneurysm
Interleukins are cytokines involved in immune and 
hematopoietic processes. As of today, several dozen 
proteins belonging to this group of compounds were 
described [66]. In the pathogenesis of AAA, interleukins 
2, 6, 10 and C-reactive protein (CRP) appear to be the 
most important. CRP is one of the most important indi-
24
Acta Angiol, 2019, Vol. 25, No. 1
www.journals.viamedica.pl/acta_angiologica
cators of inflammation. It is produced in the liver under 
the influence of interleukin 6 [67]. Oszkinis et al. [4] ana-
lyzed the concentration of interleukins 2, 6, 10 and CRP 
in individuals without AAA and in patients with AAA. 
These researchers showed a statistically significant in-
crease in interleukin 6 and CRP protein in subjects with 
AAA compared to those without AAA. In addition, there 
was a correlation between the level of interleukin 2, 
interleukin 6 and CRP protein and the diameter of the 
abdominal aortic aneurysm. In the group of patients 
with AAA, there was no statistically significant positive 
correlation between IL-10 serum concentration and the 
aneurysm diameter. In the conclusions from this study, the 
researches stated that the serum cytokines IL-2, IL-6 and 
CRP are useful for monitoring the severity of inflammatory 
lesions responsible for the increase in the diameter of the 
aneurysm. With the change in size, the aneurysm increases 
the concentration of inflammatory proteins, which may 
indicate the dependence of the aneurysm widening on the 
severity of inflammatory processes and have a significant 
impact on the decision on surgical treatment [4].
Roles of a1-antiproteinase, anti-thrombin 
III and cystatin C in the abdominal  
aorta aneurysm
One of the main components of the AAA pathogenesis 
is the disturbance of the proteolytic and antipathetic 
balance [68–77]. In the case of AAA, there is an increase 
in proteolytic mechanisms towards antiproteolytic ac-
tivity, which leads to enlargement and rupture of the 
aneurysm [78]. Proteinases are synthesized in cells of 
aortic walls, such as endothelial cells, myocytes and 
fibroblasts and in cells inflowing to the aortic wall of 
the aneurysm, mainly monocytes/macrophages, gran-
ulocytes, lymphocytes and mast cells. In the aneurysm 
wall, there are proteinases and proteinase inhibitors 
[77–79]. Gacko et al. [16] analyzed the activity of ser-
ine proteinase inhibitors (serpins) and the activity of 
cysteine proteinase inhibitors (cystatin) in diseases with 
AAA. The research group consisted of 15 people with 
AAA (mean age 65.3 years), while the control group 
consisted of 12 people without AAA at a similar age. The 
activity of inhibitors in the blood plasma was determined 
by measuring the degree of reduction of the specific 
activity of each proteinase, acting on a specific substrate. 
For the activity of inhibitors, the following were used: 
a1-antiproteinase (a1-AP) — trypsin and Cbz-DL-Arg-
pNA, a1-antichymotrypsin (a1-ACT) — chymotypsin 
and Cbz-Phe-pNA, a2-macroglobulin (a2- MG) — 
trypsin and Cbz-Val-Gly-Arg-pNA, in the presence of 
a chiral route, a2-antiplasmin (a2-APl) — plasmin and 
D-Val-Leu-Lys-pNA, antithrombin III (AT-III) — throm-
bin and fibrinogen, cystatin — papain and casein, after 
prior inactivation of a2-MG. These researchers showed 
that in plasma in patients with aortic aneurysm much 
higher activity of a1-AP than in healthy subjects, the 
activity of a1-ACT, a2-MG and a2-APl did not dif-
fer in the compared groups. However, AT-III activity 
and cystatin C activity in the blood plasma in patients 
with aortic aneurysm remained lower than in healthy 
subjects. In the results of the study, the authors state 
that the abdominal aortic aneurysm is accompanied by 
systemic reaction manifested by increased activity and 
concentration of a1-AP, decreased activity and AT-III 
concentration and decreased activity and concentration. 
cystatins in blood plasma. This indicates a proteinase 
— antiproteinase imbalance and the activation of blood 
coagulation in patients with aortic aneurysm [16].
Transcription factors are potentially 
involved in the abdominal aorta aneurysm
In the course of AAA pathological expression of many 
proteins was observed, including transcription factors 
such as ELF1, ETS2, RUNX1, STAT5. Pahl et al. [17] 
evaluated the level of selected transcription factors in 
individuals with AAA and compared them with samples 
obtained from people without AAA. These research-
ers showed that the concentration of ELF1 is 1.8 fold 
higher in people with AAA compared to healthy sub-
jects. The concentration of ETS2 factor was elevated 
1.4 times, while the RUNX1 factor was 2.5 fold higher. 
There were no differences in the STAT factor [17]. 
ELF1, ETS2, RUNX1 and STAT5 transcription factors 
are important regulators of immune cell proliferation, 
differentiation and activation [80–83]. Researchers in-
vestigated the target genes of these transcription factors 
by the use the Gene Ontology (GO) biological function 
categories. The data revealed that in the AAA tissue 
most significantly enriched biological function catego-
ries were leukocyte migration and intracellular protein 
kinase cascade [17] In the control aorta, the most sig-
nificant GO categories differed from those in the AAA 
samples and included cytoskeleton organization and 
small GTPase mediated signal transduction. The genes 
up-regulated in AAA tissue showed highly significant 
enrichment for Gene Ontology categories leukocyte 
migration, activation of the immune response, T cell 
activation and regulation of lymphocyte activation [17].
The genes downregulated in AAA were enriched 
in completely different GO categories including cy-
toskeleton organization, muscle cell development, 
organ morphogenesis and cell junction assembly [17]. 
The data provide evidence for the involvement of the 
immune system in the pathogenesis of AAA and indicate 
that ELF1, ETS2, RUNX1 and STAT5 transcriptional 
factors may be very important agents in this process.
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Summary
Many factors are involved in the pathogenesis of AAA: 
proteins, transcription factors, enzymes, and microR-
NAs. The increase in the concentration of most factors 
is associated with inflammation. Inflammation is the 
main mechanism leading to the development of AAA 
but also other diseases such as atherosclerosis, diabetes 
mellitus, hypertension, rheumatoid arthritis, etc. The 
biomarkers presented in this paper are not restricted to 
AAA, and therefore can only be used for an illustrative 
assessment of the degree of abdominal aortic aneurysm 
development. As of today, radiological tests are the only 
fully reliable tests that can be used to diagnose AAA.
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